Danish drugmaker Novo Nordisk plans to invest 8.5 billion Danish kroner (about €1.14 billion) to establish a new production facility in Odense, Denmark.
Danish biopharma company Ascendis Pharma will grant pharmaceutical giant Novo Nordisk an exclusive worldwide license to its TransCon technology platform to develop...
In order to meet significantly higher demand from its parent company Novo Nordisk, Novo Nordisk Pharmatech is planning to build a new factory at a 47,000 m² site in Køge...
Ozempic producer Novo Nordisk announced plans to invest $4.1 billion to build a second fill and finishing manufacturing facility in Clayton, North Carolina, for the...
Novo Nordisk is to acquire Cardior Pharmaceuticals for up to €1.025 billion Euros, including an upfront payment and additional payments if certain development and...
US biotechnology company Neomorph signed a $1.46 billion licensing agreement with Novo Nordisk to discover, develop and commercialize molecular glue degraders.
Novo Holdings, Novo Nordisk's parent company, is acquiring US contract development and manufacturing organization (CDMO) Catalent for $16.5 billion. The companies said...
Novo Nordisk wants to make another major capital investment in production capacity for its diabetes and obesity therapies. The Danish drugmaker announced to spend more...
